Evidence map›Paper›PMID 35303106›Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.

Artak Labadzhyan, Kristopher Wentzel, Omid Hamid, Kamlynn Chow, Sungjin Kim, Lawrence Piro, Shlomo Melmed

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.The Journal of clinical endocrinology and metabolism · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Artak LabadzhyanPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-8288-6698
Kristopher WentzelThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Omid HamidThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Kamlynn ChowThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Sungjin KimBiostatistics and Bioinformatics Core, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lawrence PiroThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.
Shlomo MelmedPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-2355-3447
Angeles Clinic and Research Institute · USCedars-Sinai Medical Center · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Training Program in Endocrinology, Diabetes, and MetabolismT32DK007770 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI MELMED, SHLOMO · 1999 to 2022
$3.4M
NCATS NIH HHS UL1 TR001881NIDDK NIH HHS T32 DK007770
6 · The paper itself

Abstract

contextIncidence and awareness of endocrine-related adverse events (ERAE) associated with use of immune checkpoint inhibitors (ICI) has grown with increased ICI use, yet mechanisms for ERAE prediction, surveillance, and development are not well established.

objectiveWe prospectively evaluated the impact of endocrine autoimmunity on ERAE development and overall survival (OS).

methodsAdults ≥ 18 years of age prescribed ICI treatment for advanced or metastatic solid tumors and no known active/past endocrine disorders were eligible for enrollment. Thyroid, adrenal, and pancreatic antibodies as well as hormone levels were assessed prior to ICI treatment and at 8 to 9 weeks and 36 weeks after treatment for ERAE in relation to presence and changes in endocrine-specific antibodies, hormone levels, and OS.

resultsSixty patients were enrolled and ERAE were detected in 14 (23.3%), with a median onset of 52 days (IQR, 38.5-71.5) after first ICI dose. Hypothyroidism occurred in 12 (20%) patients, and 2 (3.33%) patients developed hypophysitis. Diabetes and primary adrenal insufficiency were not observed. Antibodies were detected in 14 patients (11 at baseline, 3 developed during follow-up) and their presence was significantly associated with ERAE (R2 59.3%, P < 0.001). Thyroid peroxidase antibody (20%) and thyroid-stimulating immunoglobulin (3.3%) were most common, and anti-GAD was present in 1 patient. The presence of ERAE was associated with a more favorable OS (P = 0.001).

conclusionEndocrine-specific autoantibodies play an important role in ERAE pathogenesis and may serve as predictive markers for early identification and treatment of ICI-induced endocrinopathies.

Indexed as

Diabetes MellitusImmune Checkpoint InhibitorsAdultAutoantibodiesHormonesHumansProspective StudiesAutoantibodiesHormonesImmune Checkpoint Inhibitorsautoantibodiesendocrine-related adverse eventsimmune checkpoint inhibitors

Identifiers

PMID35303106
PMCPMC9202695
OpenAlexW4220851391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.